Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort
- PMID: 15384015
Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort
Abstract
Background: Uric acid may be a true mediator of renal disease and progression. However, epidemiological evidence for the significance of serum uric acid levels on the risk for developing end-stage renal disease (ESRD) is scarce in a setting of community-based screening.
Methods: Participants in a 1993 mass screening conducted by the Okinawa General Health Maintenance Association in Okinawa, Japan, were investigated: 48,177 screenees (22,949 men, 25,228 women) older than 20 years for whom serum uric acid data were available were studied. All dialysis patients treated in Okinawa were independently registered in the Okinawa Dialysis Study registry. Participants in the 1993 screening who later entered a dialysis program were identified by using 2 computer registries. The cumulative incidence of ESRD was calculated according to quartiles of baseline serum uric acid levels for each sex. The significance of hyperuricemia (serum uric acid level > or = 7.0 mg/dL [> or =416 micromol/L] in men and > or = 6.0 mg/dL [> or =357 micromol/L] in women) for the risk for developing ESRD was evaluated by means of the Cox model after adjusting for age, blood pressure, body mass index, proteinuria, hematocrit, and total cholesterol, triglyceride, fasting blood glucose, and serum creatinine levels.
Results: Mean serum uric acid level was 6.4 +/- 1.4 (SD) mg/dL (381 micromol/L) in men and 4.8 +/- 1.1 mg/dL (286 micromol/L) in women. Prevalences of hyperuricemia were 31.9% in men and 13.6% in women. By the end of 2000, a total of 103 screenees (53 men, 50 women) entered dialysis programs. Calculated incidences of ESRD per 1,000 screenees were 1.22 for men without hyperuricemia and 4.64 for men with hyperuricemia and 0.87 for women without hyperuricemia and 9.03 for women with hyperuricemia. Adjusted hazard ratios for hyperuricemia were 2.004 (95% confidence interval, 0.904 to 4.444; P = not significant) in men and 5.770 (95% confidence interval, 2.309 to 14.421; P = 0.0002) in women.
Conclusion: Screenees with hyperuricemia were associated with a greater incidence of ESRD. Hyperuricemia (serum uric acid > or = 6.0 mg/dL [> or =357 micromol/L]) was an independent predictor of ESRD in women. Strategies to control serum uric acid levels in the normal range may reduce the population burden of ESRD.
Similar articles
-
Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan.Am J Kidney Dis. 2004 Nov;44(5):806-14. Am J Kidney Dis. 2004. PMID: 15492946
-
Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in screened subjects in Okinawa, Japan.Clin Exp Nephrol. 2004 Sep;8(3):250-6. doi: 10.1007/s10157-004-0293-z. Clin Exp Nephrol. 2004. PMID: 15480903
-
Relationship between dyslipidemia and the risk of developing end-stage renal disease in a screened cohort.Clin Exp Nephrol. 2005 Mar;9(1):46-52. doi: 10.1007/s10157-004-0332-9. Clin Exp Nephrol. 2005. PMID: 15830273
-
Renal outcomes in chronic kidney disease.Nephrology (Carlton). 2010 Jun;15 Suppl 2:27-30. doi: 10.1111/j.1440-1797.2010.01308.x. Nephrology (Carlton). 2010. PMID: 20586944 Review.
-
Predictors of diabetic end-stage renal disease in Japan.Nephrology (Carlton). 2005 Oct;10 Suppl:S2-6. doi: 10.1111/j.1440-1797.2005.00447.x. Nephrology (Carlton). 2005. PMID: 16174282 Review.
Cited by
-
Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.QJM. 2013 Aug;106(8):721-9. doi: 10.1093/qjmed/hct093. Epub 2013 Apr 24. QJM. 2013. PMID: 23620537 Free PMC article.
-
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.Clin Exp Nephrol. 2015 Dec;19(6):1044-53. doi: 10.1007/s10157-015-1095-1. Epub 2015 Feb 13. Clin Exp Nephrol. 2015. PMID: 25676011 Clinical Trial.
-
Chapter 3: Management of progression and complications of CKD.Kidney Int Suppl (2011). 2013 Jan;3(1):73-90. doi: 10.1038/kisup.2012.66. Kidney Int Suppl (2011). 2013. PMID: 25598999 Free PMC article. No abstract available.
-
Obesity-related cardiorenal disease: the benefits of bariatric surgery.Nat Rev Nephrol. 2013 Sep;9(9):539-51. doi: 10.1038/nrneph.2013.145. Epub 2013 Aug 6. Nat Rev Nephrol. 2013. PMID: 23917797 Review.
-
Reduced Risk of Sepsis and Related Mortality in Chronic Kidney Disease Patients on Xanthine Oxidase Inhibitors: A National Cohort Study.Front Med (Lausanne). 2022 Jan 31;8:818132. doi: 10.3389/fmed.2021.818132. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35174186 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical